Payment overview · 2025
General Payments
$353.95
20 reported records · 6 companies
Healthcare provider profile · identity verified
Gary A Tennison, DO
Allopathic & Osteopathic Physicians|Family Medicine · ROBINSON, IL · NPI 1518946813
Verified facts
What the public records show
CMS Open Payments records show Gary A Tennison, DO received $353.95 in general payments during 2025 across 20 reported records.
Lilly USA, LLC accounted for 31.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance, Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 234 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 234 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 225 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $112.81 | 31.9% | 7 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $67.50 | 19.1% | 4 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $64.02 | 18.1% | 3 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $59.40 | 16.8% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.48 | 9.5% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $16.74 | 4.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $353.95 | 20 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $139.12 | 8 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $64.02 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $59.40 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $41.19 | 3 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $41.19 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $18.69 | 1 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $16.74 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 234 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 26 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
234 | 50 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
234 | 50 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
225 | 34 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 799 | 130 |
| Amlodipine Besylate | Amlodipine Besylate | 794 | 125 |
| Lisinopril | Lisinopril | 606 | 101 |
| Levothyroxine Sodium | Levothyroxine Sodium | 593 | 83 |
| Hydrochlorothiazide | Hydrochlorothiazide | 572 | 83 |
| Losartan Potassium | Losartan Potassium | 562 | 84 |
| Omeprazole | Omeprazole | 539 | 86 |
| Metformin Hcl | Metformin Hcl | 495 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 432 | 71 |
| Simvastatin | Simvastatin | 431 | 60 |
| Furosemide | Furosemide | 394 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 353 | 55 |
| Montelukast Sodium | Montelukast Sodium | 345 | 57 |
| Potassium Chloride | Potassium Chloride | 342 | 57 |
| Allopurinol | Allopurinol | 339 | 50 |
| Eliquis | Apixaban | 290 | 32 |
| Trazodone Hcl | Trazodone Hcl | 286 | 53 |
| Famotidine | Famotidine | 282 | 49 |
| Metoprolol Tartrate | Metoprolol Tartrate | 254 | 41 |
| Warfarin Sodium | Warfarin Sodium | 242 | 22 |
| Jardiance | Empagliflozin | 234 | 50 |
| Ozempic | Semaglutide | 225 | 34 |
| Gabapentin | Gabapentin | 220 | 38 |
| Tramadol Hcl | Tramadol Hcl | 208 | 64 |
| Citalopram Hbr | Citalopram Hydrobromide | 195 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 195 | 32 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 186 | 54 |
| Clopidogrel | Clopidogrel Bisulfate | 186 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 186 | 33 |
| Alprazolam | Alprazolam | 180 | 32 |
| Glimepiride | Glimepiride | 179 | 29 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 176 | 24 |
| Fluticasone Propionate | Fluticasone Propionate | 150 | 40 |
| Metformin Hcl Er | Metformin Hcl | 149 | 22 |
| Buspirone Hcl | Buspirone Hcl | 144 | 35 |
| Januvia | Sitagliptin Phosphate | 143 | 17 |
| Meloxicam | Meloxicam | 143 | 29 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 129 | 100 |
| Sertraline Hcl | Sertraline Hcl | 119 | 20 |
| Xarelto | Rivaroxaban | 119 | 12 |
| Carvedilol | Carvedilol | 115 | 20 |
| Lorazepam | Lorazepam | 113 | 20 |
| Alendronate Sodium | Alendronate Sodium | 111 | 16 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 110 | 110 |
| Atenolol | Atenolol | 110 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 107 | 19 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 105 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 104 | 17 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 96 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 94 | 15 |
| Benazepril Hcl | Benazepril Hcl | 91 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 88 | 13 |
| Enalapril Maleate | Enalapril Maleate | 83 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 82 | 12 |
| Myrbetriq | Mirabegron | 81 | suppressed |
| Mirtazapine | Mirtazapine | 77 | 14 |
| Pravastatin Sodium | Pravastatin Sodium | 75 | 18 |
| Clonidine Hcl | Clonidine Hcl | 73 | 14 |
| Donepezil Hcl | Donepezil Hcl | 73 | suppressed |
| Bupropion Xl | Bupropion Hcl | 72 | 11 |
| Pregabalin | Pregabalin | 71 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 69 | 17 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 69 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 69 | 11 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 69 | 43 |
| Gemfibrozil | Gemfibrozil | 68 | suppressed |
| Nifedipine Er | Nifedipine | 67 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 67 | suppressed |
| Topiramate | Topiramate | 63 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 62 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 61 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 61 | suppressed |
| Prednisone | Prednisone | 59 | 30 |
| Clonazepam | Clonazepam | 58 | suppressed |
| Ezetimibe | Ezetimibe | 58 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 57 | suppressed |
| Olanzapine | Olanzapine | 56 | suppressed |
| Temazepam | Temazepam | 56 | suppressed |
| Lovastatin | Lovastatin | 54 | suppressed |
| Celecoxib | Celecoxib | 52 | 12 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 50 | 28 |
| Risperidone | Risperidone | 50 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 49 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 49 | suppressed |
| Glipizide Er | Glipizide | 47 | suppressed |
| Irbesartan | Irbesartan | 47 | suppressed |
| Methylprednisolone | Methylprednisolone | 47 | 44 |
| Ventolin Hfa | Albuterol Sulfate | 46 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 45 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 45 | suppressed |
| Synthroid | Levothyroxine Sodium | 45 | 13 |
| Diazepam | Diazepam | 43 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 43 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 43 | suppressed |
| Levetiracetam | Levetiracetam | 42 | suppressed |
| Azithromycin | Azithromycin | 41 | 30 |
| Aripiprazole | Aripiprazole | 40 | suppressed |
| Chlorthalidone | Chlorthalidone | 40 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 40 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 39 | 34 |
| Bumetanide | Bumetanide | 39 | suppressed |
| Finasteride | Finasteride | 39 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 38 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 28 |
| Propranolol Hcl | Propranolol Hcl | 37 | suppressed |
| Valsartan | Valsartan | 37 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 36 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 35 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 35 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 35 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 34 | 28 |
| Trulicity | Dulaglutide | 33 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 32 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Latanoprost | Latanoprost | 32 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 32 | 21 |
| Terazosin Hcl | Terazosin Hcl | 32 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 31 | 26 |
| Bupropion Hcl Sr | Bupropion Hcl | 29 | suppressed |
| Cephalexin | Cephalexin | 29 | 21 |
| Diltiazem Hcl | Diltiazem Hcl | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Fenofibrate | Fenofibrate | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Acarbose | Acarbose | 27 | suppressed |
| Naproxen | Naproxen | 27 | suppressed |
| Mounjaro | Tirzepatide | 26 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 25 | 25 |
| Nitroglycerin | Nitroglycerin | 25 | 13 |
| Oxcarbazepine | Oxcarbazepine | 25 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Ondansetron Odt | Ondansetron | 24 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 24 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 23 | suppressed |
| Ketoconazole | Ketoconazole | 23 | 12 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Metolazone | Metolazone | 22 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 21 | suppressed |
| Sucralfate | Sucralfate | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Nystatin | Nystatin | 19 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 19 | suppressed |
| Primidone | Primidone | 19 | suppressed |
| Ramipril | Ramipril | 19 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 19 | suppressed |
| Torsemide | Torsemide | 19 | suppressed |
| Amoxicillin | Amoxicillin | 18 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Insulin Syringe | Syring-Needl,disp,insul,0.3 Ml | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 18 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 17 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 17 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 17 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Methimazole | Methimazole | 16 | suppressed |
| Repatha Syringe | Evolocumab | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 15 | 15 |
| Ammonium Lactate | Ammonium Lactate | 15 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | 13 |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Verapamil Sr | Verapamil Hcl | 15 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 14 | suppressed |
| Nabumetone | Nabumetone | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 14 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Balsalazide Disodium | Balsalazide Disodium | 13 | suppressed |
| Carbamazepine Er | Carbamazepine | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Paroxetine Er | Paroxetine Hcl | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 13 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Fentanyl | Fentanyl | 12 | suppressed |
| Folic Acid | Folic Acid | 12 | suppressed |
| Isibloom | Desogestrel-Ethinyl Estradiol | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Novolog | Insulin Aspart | 12 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 12 | suppressed |
| Tadalafil | Tadalafil | 12 | suppressed |
| Turqoz | Norgestrel-Ethinyl Estradiol | 12 | suppressed |
| Amantadine | Amantadine Hcl | 11 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $353.95 · 20 records | Lilly USA, LLC | BREZTRI, INGREZZA, JARDIANCE, LEQVIO, MOUNJARO, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error